Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Acorda Therapeutics, Inc. (NQ: ACOR)
32.23 USD  -0.71 (-2.16%)
Streaming Delayed Price  /  Updated: 1:43 PM EDT, May 20, 2013  /  Add to My Watchlist      
View: Quote News Research
Press releases about Acorda Therapeutics, Inc.
 
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Acorda Therapeutics to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
November 16, 2009
from Business Wire News Releases
Acorda Therapeutics Reports Third Quarter 2009 Financial Results
November 03, 2009
Positive Vote by U.S. Food and Drug Administration (FDA) Advisory Committee for Fampridine-SR on October 14 Read More
from Business Wire News Releases
Acorda Therapeutics to Host Conference Call to Report Third Quarter 2009 Financial Results on November 3, 2009
October 27, 2009
from Business Wire News Releases
Acorda Therapeutics Announces Extension of Fampridine-SR PDUFA Goal Date to January 22, 2010
October 22, 2009
from Business Wire News Releases
PicksThatMove.com Announces Investment Opinion Hot Stocks on NVNC, MPG, ACOR, KNA and ROYL
October 16, 2009
from Business Wire News Releases
StockSource.us Reports on MNDP -- Pioneering Surveillance Technologies
October 16, 2009
NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the IO News Wire. Read More
from Marketwired News Releases
Acorda Therapeutics Announces Positive Vote by FDA Advisory Committee for Fampridine-SR
October 14, 2009
from Business Wire News Releases
Acorda Therapeutics Stock Trading Halted Today; FDA Advisory Committee to Review Fampridine-SR for Improvement of Walking Ability in People with Multiple Sclerosis
October 14, 2009
from Business Wire News Releases
Acorda Therapeutics Announces Posting of Briefing Documents for October 14 FDA Advisory Committee Meeting on Fampridine-SR
October 09, 2009
from Business Wire News Releases
Acorda Therapeutics Announces Data on Retention Rates and Safety from Two Phase 3 Fampridine-SR Extension Studies
September 15, 2009
from Business Wire News Releases
Acorda Therapeutics Announces Interim Analysis of Two-Year Efficacy and Safety Data from Phase 3 Fampridine-SR Extension Study
September 10, 2009
from Business Wire News Releases
Acorda Therapeutics Reports Date of FDA Advisory Committee Review of Fampridine-SR for Improvement of Walking Ability in People with MS
August 25, 2009
from Business Wire News Releases
Acorda Therapeutics Names Ruhi Kahn as Vice President, Business Development
August 05, 2009
from Business Wire News Releases
Acorda Therapeutics Reports Second Quarter 2009 Financial Results
August 04, 2009
from Business Wire News Releases
Acorda Therapeutics to Host Conference Call to Report Second Quarter 2009 Financial Results on August 4, 2009
July 28, 2009
from Business Wire News Releases
Biogen Idec and Acorda Therapeutics Announce Collaboration Agreement to Develop and Commercialize MS Therapy Fampridine-SR in Markets Outside the U.S.
July 01, 2009
from Business Wire News Releases
BenchmarkJournal.com (Complimentary) Analyst Review for ACOR, EXTR, ERES, DRIV, CKSW and CHLN
June 29, 2009
NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Benchmark Journal. Read More
from Marketwired News Releases
Acorda Therapeutics Announces Eligibility of Fampridine-SR for Centralized Review in Europe
June 08, 2009
from Business Wire News Releases
Zacks Bull & Bear of the Day Highlights: Acorda Therapeutics, Corp. Executive Board, Amazon.com, Pearson Plc and John Wiley & Sons
May 07, 2009
from Business Wire News Releases
Zacks Analyst Blog Highlights: Bank of America, Citigroup, Microsemi Corp., Acorda Therapeutics, Inc. and Web.com
May 07, 2009
from Business Wire News Releases
Acorda Therapeutics Reports First Quarter 2009 Financial Results
May 06, 2009
from Business Wire News Releases
Acorda Therapeutics Announces FDA Acceptance of Fampridine-SR New Drug Application for Filing
May 06, 2009
from Business Wire News Releases
Study Highlights Economic Impact of Early Mobility Impairment in People with Multiple Sclerosis
April 29, 2009
from Business Wire News Releases
Acorda Therapeutics to Host Conference Call to Report First Quarter 2009 Financial Results on May 6, 2009
April 29, 2009
from Business Wire News Releases
TheFortuneFinancial.com Initializes Free Analyst Research on ACOR, ARNA, SCHN and STLD
April 27, 2009
NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by TheFortuneFinancial.com. Read More
from Marketwired News Releases
Acorda Therapeutics Resubmits New Drug Application for Fampridine-SR for Improvement of Walking Ability in People with Multiple Sclerosis
April 23, 2009
from Business Wire News Releases
Acorda Therapeutics to Present at the New York Biotechnology Association 18th Annual Meeting
April 16, 2009
from Business Wire News Releases
Acorda Therapeutics Names Anthony Caggiano Vice President, Preclinical Development
April 10, 2009
from Business Wire News Releases
Zacks Bull &amp; Bear of the Day Highlights: Acorda Therapeutics, The St. Joe Company, Citigroup, Bank of America and Wells Fargo
April 02, 2009
from Business Wire News Releases
Zacks Analyst Blog Highlights: The Governor and Company of the Bank of Ireland, Eli Lilly &amp; Co., Acorda Therapeutics, Linktone and Chesapeake Energy Corp.
April 02, 2009
from Business Wire News Releases
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here